|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Summary of findingstabel |  |  |  |  |  |  |  |  |  |  |  |
| Skema til GRADERING af evidensen i KKR LA intraartikulært efter artroskopisk knækirurgi | Søjler med **FED overskrift er obligatorisk** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|   |  Summary of findings |   |
|  Quality assessment (GRADE) |  No of patients |  Effect |   |   |
|   | Intervention | comparator | Relative  | Absolute |   |
|   | (95 % CI) |   |
| **Navn på studie** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Publication** |   |   |   |   |  **Quality** |   |
|  |
| Outcome: Primære outcome: VAS , ketamin + levobupivacain vs placebo og ketamin vs placebo |
|   |
| Cengiz Isik et al. | RCT | 2 | **NA** | **1** | **0** | 0 | 20/20 | 20 | NA | Unclear | Low |   |
|
|
|
|
|
|
|
|   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outcome: Primære outcome: VAS , morfin vs placebo |  |  |  |  |  |  |  |  |  |  |
| Zou et al. | Systematisk review  | 1 | 0 | 0 | 0 | 0 | 152 | 145 | NA | No difference, non significant | High |   |
|   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outcome: Primære outcome: VAS , bupivacain vs placebo |  |  |  |  |  |  |  |  |  |
| Qi-bin Sun et al | Systemaitksk review | 1 | 0 | 0 | 0 | 0 | 786 | 774 | NA | 2h = - 1,07 4h =-0,83 6h= -0,49 12h = -0,4 24h = -0,35 | High | (All significant) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outcome: Primære outcome: VAS , ropivacain vs placebo samt brug af supplerende smertestillende |  |  |  |  |  |  |  |
| Yang Zhou et al.  | Systematisk review | 0 | 0 | 0 | 0 | 0 | 101 / 187 | 102/192 | NA | 0-2h = -1,0 2-8h = -1,19 8-24h = -0,7 (not significant). No significant difference in supplementary analgesia | High |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |